Democratic Underground Latest Greatest Lobby Journals Search Options Help Login
Google

New Drugs at CROI (Retrovirus Conference, Feb., LA)

Printer-friendly format Printer-friendly format
Printer-friendly format Email this thread to a friend
Printer-friendly format Bookmark this thread
Home » Discuss » DU Groups » Health & Disability » HIV/AIDS Support Group Donate to DU
 
pinto Donating Member (1000+ posts) Send PM | Profile | Ignore Fri May-18-07 05:56 PM
Original message
New Drugs at CROI (Retrovirus Conference, Feb., LA)
New Drugs at CROI: The Four Musketeers
New drugs, new targets, new hope

by Jeff Berry

The most exciting news to come out of the 14th Retrovirus Conference held in Los Angeles during February related to new drugs currently in development, including two integrase inhibitors, an entry inhibitor, and a second-generation non-nucleoside. Dr. John Mellors of the University of Pittsburgh introduced the late breaker session on Tuesday evening, remarking, I dont think its an understatement to say that this session marks a milestone in the treatment of HIV in resistant patients.

Raltegravir

In the late breaker session on Tuesday, David Cooper, MD of the University of New South Wales in Sydney, Australia presented 16 and 24-week data from Phase 3 studies of Mercks integrase inhibitor raltegravir (formerly known as MK-0518). Integrase inhibitors belong to a new class of drugs that target HIV at a different point in the HIV lifecycle.

Maraviroc

Also at Tuesdays late breaker session, Howard Mayer, MD of Pfizer presented 24-week data on their oral CCR5 antagonist maraviroc, which belongs to an entirely new class of drug that blocks HIV at the point of entry into the CD4 cell.

Elvitegravir

Andrew Zolopa, MD of the Stanford University School of Medicine presented 24-week data on the Phase 2b study of Gileads integrase inhibitor elvitegravir, formerly known as GS-9137.

TMC-278

Anton Pozniak, MD of Chelsea and Westminster Hospital in London, UK gave a late breaker presentation on TMC-278, Tibotecs second generation non-nucleoside that is currently in a randomized, controlled Phase 2b dose-finding study in treatment-nave patients.

< full article, conference coverage at Test Positive Aware Network (TPAN) website: >

http://tpan.com/publications/pa/07_03/new_drugs.shtml
Refresh | 0 Recommendations Printer Friendly | Permalink | Reply | Top

Home » Discuss » DU Groups » Health & Disability » HIV/AIDS Support Group Donate to DU

Powered by DCForum+ Version 1.1 Copyright 1997-2002 DCScripts.com
Software has been extensively modified by the DU administrators


Important Notices: By participating on this discussion board, visitors agree to abide by the rules outlined on our Rules page. Messages posted on the Democratic Underground Discussion Forums are the opinions of the individuals who post them, and do not necessarily represent the opinions of Democratic Underground, LLC.

Home  |  Discussion Forums  |  Journals |  Store  |  Donate

About DU  |  Contact Us  |  Privacy Policy

Got a message for Democratic Underground? Click here to send us a message.

© 2001 - 2011 Democratic Underground, LLC